Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 Multiple Myeloma Highlights
31 January 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in multiple myeloma from ASH 2023
The Post-ASH 2023 Multiple Myeloma Highlights was supported by Legend Biotech. Supporters have no influence over the production of content.
Session 1: Precursors
Immuno-PRISM: BsAbs in HR smoldering myeloma
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
GEM-CESAR: peripheral blood residual disease status predicts outcome
Noemí Puig University Hospital Salamanca, Salamanca, Spain
Genomic profiling for early intervention in HR smoldering myeloma
Benjamin Diamond Sylvester Comprehensive Cancer Center, Miami, FL, United States
Serum biomarkers on the risk of progression in smoldering myeloma
Malin Hultcrantz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Panel discussion: precursors
Session 2: Approved CARs
CARTITUDE-2: cilta-cel for pts with myeloma and 1-3 prior lines of therapy
Jens Hillengass Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
CARTITUDE-4: cilta-cel vs SoC in pts w/ LEN-refractory myeloma
Roberto Mina University of Turin, Turin, Italy
Outcomes after CAR T-cells in pts with extramedullary/paramedullary disease
Darren Pan Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Peak cytokines associated w/ toxicity & early responses
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Panel discussion: approved CARs
Session 3: Novel agents
BMS-986393 CAR T-cell therapy for R/R myeloma
Susan Bal University of Alabama, Birmingham, AL, United States
CART-ddBCMA for R/R myeloma: 1-year follow-up
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
CARTBCMA-HCB-01: Cesnicabtagene autoleucel for R/R myeloma
Aina Oliver-Caldés Son Espases Hospital, Illes Balears, Spain
EMN26: iberdomide maintenance after ASCT in newly diagnosed myeloma
Niels van de Donk VU University Medical Center, Amsterdam, Netherlands
Dose escalation of HPN217 targeting BCMA for R/R myeloma
Sumit Madan Banner MD Anderson Cancer Center, Mesa, AZ, United States
Panel discussion: novel agents
Session 4: Combinations
EMN20: KRd vs Rd in newly diagnosed fit/intermediate-fit myeloma pts
Benedetto Bruno University of Torino, Torino, Italy
GEM2017FIT: VMP & Rd vs KRd +/- D, with LEN + D as consolidation
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
MonumenTAL-1: talquetamab + pomalidomide for R/R myeloma
Jeffrey Matous Colorado Blood Cancer Institute, Denver, CO, United States
Panel discussion: combinations
Session 5: Assessment and stratification techniques
Minimally invasive assessment of MRD in multiple myeloma
Carmen Gonzalez University of Navarra, Pamplona, Spain
Towards a decision engine for therapeutic optimization of R/R myeloma
Yael Cohen Sourasky Medical Center, Tel-Aviv, Israel
Panel discussion: assessment and stratification techniques
The Post-ASH 2023 Multiple Myeloma Highlights has been supported by:
